Together, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical Faculty Physicians have embarked on a journey to reimagine cancer care in our region, expand access to life-changing treatment, and harness the power of scientific discovery. Our transformative plans include building New England's only dedicated, free-standing cancer hospital.
Over the past several weeks, we have reached a number of important milestones in the regulatory process, including today's meeting of the Health Policy Commission (HPC) and the release of a preliminary Cost and Market Impact Review of our collaboration. We are thankful for the HPC staff's thoughtful and robust analysis.
We also appreciate the recently released Department of Public Health (DPH) staff report, which found that Dana-Farber has met all of the required Determination of Need factors and recommends approval of the new cancer hospital, which will expand access to high-quality, cost-effective cancer care.
Known the world over for our revolutionary discoveries, groundbreaking innovations, and highly specialized patient care, Dana-Farber's clinical collaboration with BIDMC and HMFP will help address the urgent demand for adult inpatient beds for cancer care and ensure expanded access. We look forward to continuing to work collaboratively with the HPC, DPH, and the City of Boston to realize our vision for reducing the burden of cancer.
